» Articles » PMID: 27401521

Defining Secondary Progressive Multiple Sclerosis

Abstract

A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.

Citing Articles

Modulation of NCX1 expression in monocytes associates with multiple sclerosis progression.

Rubino V, Cammarota M, Criscuolo C, Cianflone A, De Martino M, de Rosa V Heliyon. 2025; 11(4):e42332.

PMID: 40041001 PMC: 11876900. DOI: 10.1016/j.heliyon.2025.e42332.


MRI versus relapse: optimal activity monitoring for management of progressive multiple sclerosis.

Giovannoni G, Hetherington S, Jones E, Dominguez Castro P, Karu H, Ansari S Brain Commun. 2025; 7(1):fcaf010.

PMID: 39906569 PMC: 11791681. DOI: 10.1093/braincomms/fcaf010.


Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.

Filippi M, Amato M, Avolio C, Gallo P, Gasperini C, Inglese M J Neurol. 2025; 272(2):179.

PMID: 39891770 PMC: 11787267. DOI: 10.1007/s00415-025-12917-4.


No Relation Between Cognitive Impairment, Physical Disability and Serum Biomarkers in a Cohort of Progressive Multiple Sclerosis Patients.

Gajewski B, Karlinska I, Domowicz M, Bednarski I, Swiderek-Matysiak M, Stasiolek M Biomolecules. 2025; 15(1).

PMID: 39858462 PMC: 11763174. DOI: 10.3390/biom15010068.


Machine learning for refining interpretation of magnetic resonance imaging scans in the management of multiple sclerosis: a narrative review.

Szekely-Kohn A, Castellani M, M Espino D, Baronti L, Ahmed Z, Manifold W R Soc Open Sci. 2025; 12(1):241052.

PMID: 39845718 PMC: 11750376. DOI: 10.1098/rsos.241052.